Please assess the completion status of the following clinical trial:

Trial Title: Cryocompression Therapy for Peripheral Neuropathy in Patients With Multiple Myeloma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DEVICE_FEASIBILITY
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have histologically or cytologically confirmed multiple myeloma (any International Staging System \[ISS\] stage).~* Clinical symptoms of bortezomib-induced peripheral neuropathy as measured by the NCI-CTCAE.~Cohort 1: Patients with clinically documented CTCAE grade greater than or equal 2 neuropathy.~Cohort 2: Patients with clinically documented CTCAE grade 1-2 neuropathy.~• Currently or previously received bortezomib-containing regimen~Cohort 1: Patients who have previously received a bortezomib-containing regimen and have clinically documented neuropathy that is attributed to the bortezomib containing regimen.~Cohort 2: Patients who are currently receiving a bortezomib-containing regimen and have clinically documented neuropathy that is attributed to the bortezomib containing regimen.~* Age must be greater than or equal to 18 years.~* Eastern Cooperative Oncology Group (ECOG) =\< 4.~* Life expectancy \>= 6 months.~* Ability to understand and the willingness to sign an Institutional Review Board (IRB)-approved informed consent document.~Exclusion Criteria:~* Self-reported or documented history of pre-existing peripheral neuropathy prior to initiation of bortezomib therapy.~* Other explanatory etiology for neuropathy.~* Presumptive evidence of congestive heart failure.~* Current deep vein thrombosis or pulmonary embolism (diagnosed within the past 6 months).~* Current pulmonary edema.~* Unable to provide accurate medical history.~* Pregnant women are excluded from this study because they will not be receiving myeloma standard of care (SOC) therapy or bortezomib-based therapy per inclusion criteria.~* Current or previously documented inflammatory phlebitis; thrombophlebitis; decompensated cardiac insufficiency; arterial dysregulation; erysipelas; carcinoma or carcinoma metastasis in the affected extremity; decompensated hypotonia; venous or arterial occlusive disease; or Raynaud's disease;~* Current monoclonal gammopathy of undetermined significance (MGUS), Waldenstroms macroglobulinemia, or Castleman disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1 VascuTherm5 vascular compression device (Type: EXPERIMENTAL): VascuTherm5 vascular compression device Cohort 1 - Grade 2-3 neuropathy - Patients with established neuropathy (e.g. previously received bortezomib-based chemotherapy and have clinically documented CTCAE grade 2 or 3 neuropathies. Patients undergo home cryocompression therapy treatments using VascuTherm device on their non-dominant hand and foot over 30 minutes daily for 8 weeks.
- Cohort 2 VascuTherm5 vascular compression device (Type: EXPERIMENTAL): VascuTherm5 vascular compression device Cohort 2 Grade 1-2 Neuropathy - Patients with new-onset neuropathy (e.g. currently receiving bortezomib-based chemotherapy have clinically documented CTCAE grade 1 or grade 2 neuropathy to explore its role in preventing worsening of CIPN in patients receiving neurotoxic chemotherapy. Patients undergo home cryocompression therapy treatments using VascuTherm device on their non-dominant hand and foot over 30 minutes daily for 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).